Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MACK NASDAQ:MYGN NASDAQ:RGLS NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMACKMerrimack Pharmaceuticals$15.13$14.82$11.53▼$15.89$223.77M1.45396,929 shsN/AMYGNMyriad Genetics$5.67+46.5%$4.91$3.76▼$29.30$356.73M1.891.42 million shs15.60 million shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/AZBIOZenas BioPharma$15.70-2.4%$11.92$5.83▼$26.25$673.11MN/A157,958 shs117,196 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMACKMerrimack Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MYGNMyriad Genetics+46.51%+40.00%+7.18%+40.69%-78.16%RGLSRegulus Therapeutics0.00%0.00%0.00%+3.95%+436.84%ZBIOZenas BioPharma-2.42%-0.32%+60.37%+69.18%+1,569,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMYGNMyriad Genetics3.821 of 5 stars3.12.00.04.12.91.70.6RGLSRegulus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZBIOZenas BioPharma1.5688 of 5 stars3.50.00.00.01.90.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMACKMerrimack Pharmaceuticals 0.00N/AN/AN/AMYGNMyriad Genetics 2.13Hold$14.38153.70% UpsideRGLSRegulus Therapeutics 2.29Hold$8.504.17% UpsideZBIOZenas BioPharma 3.00Buy$36.67133.55% UpsideCurrent Analyst Ratings BreakdownLatest MACK, RGLS, ZBIO, and MYGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025MYGNMyriad GeneticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.005/16/2025ZBIOZenas BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.005/15/2025ZBIOZenas BioPharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$35.005/8/2025MYGNMyriad GeneticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform5/7/2025MYGNMyriad GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$18.005/7/2025MYGNMyriad GeneticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/7/2025MYGNMyriad GeneticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.005/7/2025MYGNMyriad GeneticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $7.005/7/2025MYGNMyriad GeneticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$22.00 ➝ $6.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AMYGNMyriad Genetics$837.60M0.62$1.47 per share3.87$7.70 per share0.74RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AZBIOZenas BioPharma$15M43.79N/AN/A$7.48 per share2.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMACKMerrimack Pharmaceuticals-$1.18M$13.871.09∞N/AN/A-1.93%-1.78%N/AMYGNMyriad Genetics-$127.30M-$1.12N/AN/AN/A-47.45%-4.58%-3.14%N/ARGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%N/AZBIOZenas BioPharma-$156.99M-$3.55N/A∞N/AN/AN/AN/A8/21/2025 (Estimated)Latest MACK, RGLS, ZBIO, and MYGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025ZBIOZenas BioPharma-$1.02N/AN/AN/AN/AN/A8/14/2025Q2 2025RGLSRegulus Therapeutics-$0.23N/AN/AN/AN/AN/A5/15/2025Q1 2025ZBIOZenas BioPharma-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 million5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/AZBIOZenas BioPharma$0.050.31%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMACKMerrimack PharmaceuticalsN/A10.7810.78MYGNMyriad Genetics0.081.901.71RGLSRegulus TherapeuticsN/A16.3116.31ZBIOZenas BioPharmaN/A6.476.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMACKMerrimack Pharmaceuticals63.97%MYGNMyriad Genetics99.02%RGLSRegulus Therapeutics92.38%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipMACKMerrimack Pharmaceuticals30.57%MYGNMyriad Genetics2.40%RGLSRegulus Therapeutics4.35%ZBIOZenas BioPharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMACKMerrimack Pharmaceuticals42614.79 million10.27 millionOptionableMYGNMyriad Genetics2,70092.18 million89.97 millionOptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableZBIOZenas BioPharmaN/A41.83 million34.93 millionN/AMACK, RGLS, ZBIO, and MYGN HeadlinesRecent News About These CompaniesZenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8.8% - Should You Sell?August 6 at 5:52 PM | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 10.2% - What's Next?August 5 at 5:57 PM | marketbeat.com3 Highly Shorted Stocks That Could Be the Next Wall Street SensationsAugust 2, 2025 | msn.comZenas BioPharma (NASDAQ:ZBIO) Trading Up 5.3% - Here's WhyJuly 29, 2025 | marketbeat.comZenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MSJuly 28, 2025 | seekingalpha.comZenas BioPharma (NASDAQ:ZBIO) Shares Down 6.5% - Time to Sell?July 26, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 11.2% - Here's WhyJuly 14, 2025 | marketbeat.comInnovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharmaJuly 3, 2025 | tipranks.comZenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2025 | globenewswire.comZBIO DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 ...June 17, 2025 | stockhouse.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 17, 2025 | prnewswire.comInvestors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)June 16, 2025 | accessnewswire.comAZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 16, 2025 | globenewswire.comZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineJune 16, 2025 | globenewswire.comJune 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & KorsinskyJune 16, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 16, 2025 | accessnewswire.comAFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaJune 16, 2025 | businesswire.comSecurities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025June 16, 2025 | accessnewswire.comAZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 16, 2025 | prnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Zenas BioPharma, Inc. (ZBIO) Investors of June 16, 2025 DeadlineJune 16, 2025 | accessnewswire.comAFINAL REMINDER ZBIO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Zenas BioPharma, Inc. Investors to Participate in the Class Action LawsuitJune 16, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeMACK, RGLS, ZBIO, and MYGN Company DescriptionsMerrimack Pharmaceuticals NASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Myriad Genetics NASDAQ:MYGN$5.67 +1.80 (+46.51%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$5.79 +0.12 (+2.12%) As of 08/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Regulus Therapeutics NASDAQ:RGLSRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Zenas BioPharma NASDAQ:ZBIO$15.70 -0.39 (-2.42%) As of 08/6/2025 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
